PixCell Medical

Company Overview

Snapshot

Founded in June 2008 by Avishay Bransky, PixCell Medical operates with 51–200 employees. The company raised a total of $7.5M across 6 funding rounds and was acquired by Soulbrain Holdings in May 2021.

Business overview

PixCell Medical develops portable medical diagnostic products for point-of-care testing, primarily focusing on complete blood count (CBC) tests. Its core product, the HemoScreen hematology analyzer, provides lab-quality precision with a small, simple diagnostic device, delivering fast and accurate analysis for five-part differential CBC tests using a single drop of blood. The HemoScreen offers insights on 20 standard blood count parameters and comprehensive abnormal cell flagging, enhancing accessibility to CBC testing and reducing diagnostic turnaround time. Utilizing patented Viscoelastic Focusing technology and AI-powered machine-vision technology, PixCell Medical aims to enable earlier detection of complex diseases such as leukemia, lymphoma, and other cancers and infections, serving the healthcare and life sciences sectors, including providers and patients.

Strategic signal

In November 2022, PixCell Medical's HemoScreen hematology analyzer demonstrated superior performance in flagging abnormal white blood cells compared to the Sysmex XN, a leading lab hematology analyzer. This peer-reviewed validation underscores the HemoScreen's potential to significantly advance point-of-care diagnostics, offering a high-accuracy, rapid solution that can improve patient outcomes by enabling faster and more reliable detection of critical health conditions outside traditional laboratory settings.

Company Intelligence Q&A

What was a significant recent development for PixCell Medical's HemoScreen?

In November 2022, PixCell Medical's HemoScreen surpassed the Sysmex XN, a leading lab hematology analyzer, in flagging abnormal white blood cells, indicating a significant advancement in point-of-care diagnostic capabilities.

When was PixCell Medical acquired and by whom?

PixCell Medical was acquired by Soulbrain Holdings in May 2021.

What was the outcome of a clinical evaluation for HemoScreen in psychiatric diagnostics?

In December 2022, a clinical evaluation concluded that PixCell Medical's HemoScreen is an accurate and easy-to-use point-of-care analyzer for psychiatric companion diagnostics.

Did PixCell Medical receive any grants recently?

In February 2022, PixCell Medical was awarded a grant by the International Health-Tech Pilot Program.

What was a key partnership for PixCell Medical in Europe?

In April 2021, PixCell Medical partnered with Axonlab to distribute its HemoScreen point-of-care hematological analyzer across Europe.